药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Lampalizumab
The risk or severity of adverse effects can be increased when Lampalizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sirukumab
The risk or severity of adverse effects can be increased when Sirukumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tremelimumab
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Solanezumab
The risk or severity of adverse effects can be increased when Solanezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Onartuzumab
The risk or severity of adverse effects can be increased when Onartuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Depatuxizumab mafodotin
The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bapineuzumab
The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Durvalumab
The risk or severity of adverse effects can be increased when Durvalumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Figitumumab
The risk or severity of adverse effects can be increased when Figitumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ficlatuzumab
The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tabalumab
The risk or severity of adverse effects can be increased when Tabalumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Conatumumab
The risk or severity of adverse effects can be increased when Conatumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Human Varicella-Zoster Immune Globulin
The risk or severity of adverse effects can be increased when Human Varicella-Zoster Immune Globulin is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tetanus Immune Globulin
The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Trastuzumab deruxtecan.